462 results about "Angiotensin-converting enzyme" patented technology

Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.

This invention relates to novel compounds, compositions containing the compounds, that inhibit dipeptidyl peptidase (especially DPP-IV) and neprilysin (NEP, neutral endopeptidase) as well as dipeptidyl peptidase (especially DPP-IV) and angiotensin converting enzyme (ACE) and/or dipeptidyl Peptidase (especially DPP-IV) and vasopeptidases (especially ACE and NEP). These compounds and pharmaceutical compositions thereof are useful for the treatment as well as the prevention of type 2 diabetes mellitus.

The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.

The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.

Restenosis is inhibited through local delivery of anti-restenotic agents including angiotensin converting enzyme inhibitors; nicotine receptor agonists, agents that increase concentrations of nitric oxide, anti-angiogenic agents, agonists of the TGF-beta receptor; death domain receptor ligands; and thrombin inhibitors. In one embodiment of the invention, the localized delivery is effected through the use of a stent modified for delivery of the agent at the site of injury from balloon angioplasty.

Antisense oligonucleotides specific for mammalian ACE mRNA have been identified. Administration of these oligonucleotides to animals resulted in a decrease in blood pressure, but no significant change in heart rate. Methods for discovering other oligonucleotides with the same activity are taught, as are uses of the antisense molecules for treatment of human and animal diseases.

A pharmaceutical composition comprising an inhibitor of angiotensin converting enzyme and neutral endopeptidase, such as sampatrilat, and at least one bioavailability enhancer such as an organic acid, e.g., ascorbic acid. Such a composition has improved systemic bioavailability.

The present invention relates to a method of treating or preventing unscheduled bleeding in women, the unscheduled bleeding being the result of repeated administration of a hormonal composition that contains a progestogen, wherein the method includes the administration of an effective amount of Renin Angiotensin System (RAS) suppressor selected from angiotensin converting enzyme inhibitors; angiotensin II receptor antagonists; renin inhibitors and combinations thereof. Other aspects of the invention relate to a pharmaceutical composition containing a RAS suppressor and a progestogen and to a pharmaceutical kit having a plurality of dosage units, wherein at least one dosage unit contains a progestogen; at least one dosage unit contains an estrogen; and at least one dosage unit contains a RAS suppressor.

The invention provides a functional geese fermented sausage and a preparation method thereof. The preparation method of the fermented sausage is characterized by comprising the following steps: killing geese, burning the geese to remove feathers, removing viscera, washing and cleaning the geese; then taking out the white and dark meat, spreading a mixture of nitrite and sodium erythorbate on the geese, pickling the geese in a refrigerator at 0-4 DEG C 15-18 hours, mincing, performing cut-mixing and inoculating the geese; filling the geese into a sausage casing and fermenting; and roasting andcooling the sausage, thus obtaining the geese fermented sausage product with the functions of resisting oxidation, resisting angiotensin converting enzyme (ACE) and regulating immune. The preparationmethod comprises the following steps in sequence: preparing a fermenting agent, preparing the geese, pickling, rolling, performing vacuum cut-mixing, filling the geese into the sausage casing, fermenting and finally ripening, thus obtaining the functional geese fermented sausage. The invention has the following advantage: the method for preparing the fermented sausage with the functions of resisting oxidation, resisting ACE and regulating immune by utilizing the geese is disclosed for the first time.

The present invention relates to the cloning of human pro-protein converting enzyme 5 (PC5) CDNA isolated from human adrenal gland messenger RNA. Additionally, this invention relates to a method for reducing restenosis occurring at an injured vascular site comprising delivering to the injured site an antisense nucleic acid to suppress the expression of human PC5.

The invention relates to a protein for resisting SARS-CoV-2 infection and a vaccine, and belongs to the field of medicines. The problem of lack of effective prevention and treatment drugs for SARS-CoV-2 infection is solved. On one hand, the protein for resisting SARS-CoV-2 infection contains a structural domain combined with an angiotensin converting enzyme 2 receptor in an S protein of SARS-CoV-2, and the first amino acid arginine at the N end of the structural domain can be deleted. On the other hand, the vaccine for preventing and/or treating the SARS-CoV-2 infection contains the protein for resisting the SARS-CoV-2 infection, and pharmaceutically acceptable auxiliary materials or auxiliary components. According to the protein for resisting SARS-CoV-2 infection and the vaccine, the combination of the S protein of the SARS-CoV-2 and an ACE2 receptor of a host cell is blocked by inducing in-vivo generation of antibodies and other immune responses, so that a host is helped to resist coronavirus infection.

The invention discloses an angiotensin converting enzyme inhibitory peptide, which is characterized by comprising the following amino acid sequences: SEQ NO1: Arg-Leu-Ser-Phe-Asn-Pro, SEQ NO2: Leu-Leu, and SEQ NO3: Ala-Leu-Pro-Met-His-Ile-Arg. The method for preparing the inhibitory peptides comprises the following steps of: (1) preparing lactalbumin concentrated solution; (2) preparing lactalbumin hydrolysis liquid; (3) preparing angiotensin converting enzyme-containing inhibitory peptide concentrated solution; (4) performing separation and purification on the inhibitory peptide-containing concentrated solution through gel chromatography and reverse-phase high-pressure liquid chromatography; and (5) obtaining the product by freeze drying. The invention has the advantages that: three amino acid sequences of the angiotensin converting enzyme inhibitory peptide derived from the lactalbumin are disclosed for the first time, the preparation cost is low and the extraction ratio is high.

The invention discloses a method for preparing oat active peptide. The method comprises the following steps of: adding water into oat bran used as a raw material and extracting, adding amylase and beta-glucanase and performing enzymolysis, performing alkaline extraction of oat protein, performing centrifugal separation, performing isoelectric precipitation on centrifugate, centrifuging to obtain oat protein, redissolving the oat protein, performing selective enzymatic hydrolysis to obtain oat polypeptide, ultrafiltering and enriching the oat polypeptide, and freeze-drying to obtain the oat active peptide powder. The molecular weight of the obtained oat small-molecule peptide is 1,000 to 5,000Da, and the purity is 80 to 95 percent. The oat active peptide can inhibit angiotensin converting enzyme (ACE), has the effects of preserving moisture, promoting metabolism of cells and the like, and can be widely applied to the fields of blood pressure reducing health-care foods.

The present invention concerns the use of Provided is a drug composition and a method for using the composition for the prevention and the therapy of neurodegenerative diseases. The combination comprises at least two of the following substances: α-lipoic acid; ambroxol and one or several inhibitor(s) of the angiotension-converting enzyme (ACE).

This invention discloses a new Lactobacillus plantarum strain CW006(conservation number CCTCC M 206032) with an antihypertensive effect, and the hygienic and medical agents related, belonging to the micro-biological additives technological field. This Lactobacillus plantarum strain CW006 has a proteolysis activity and can acquire the antihypertensive effect by producing angiotensin-converting enzyme inhibitor via fermentation of raw milk. With these characteristics, it can be used as starting strain in the dairy industry, and applied in various health care products and medical agents as theraputic additives.

The invention relates to a pharmaceutical composition used for lowering blood pressure. The pharmaceutical composition with azilsartan medoxomil and another one or two blood pressure lowering substances as active ingredients mainly comprises calcium ion antisticking agent, angiotensin converting enzyme inhibitor (ACEI) and hydrochlorothiazide. The composition provided by the invention can be prepared into an oral preparation and is used for treating vascular hypertension.

The invention discloses a novel coronavirus SARS-CoV-2 S protein detection method. SARS-CoV-2 virus depends on spike protein on the surface to be combined with angiotensin converting enzyme 2 on the surface of a cell so as to enter the cell; according to the method, raw materials commonly used in chemiluminescence immunoassay and ACE2 are easy to purchase from the market, the biotin labeling and the alkaline phosphatase labeling are rapid, the reagent for SARS-CoV-2 S protein detection can be rapidly prepared, and the positive coincidence rate, the negative coincidence rate and the total coincidence rate are high compared with the SARS-CoV-2 fluorescence quantitative PCR result.

Granules and tablets for oral administration, containing angiotensin-converting enzyme inhibiting peptides and treated whey with a mixing fluid bed processor, wherein said whey is obtained from lactic acid fermentation liquid. The granules have properties of narrow particle distributions, low moisture absorption, and heavy specific gravity, as well as high free flowing. A process is also provided for producing the granules by the steps of:a) onto seed granules obtained in an earlier operation in a mixing fluid bed processor, spraying purified whey of lactic acid fermentation liquid to form preliminary granules;b) treating the preliminary granules thus obtained to reduce particle size in a size reduction mill;c) returning the treated powder to the mixing fluid bed processor, and,d) spraying additional purified whey onto the returned powder in the mixing fluid bed processor to form granules, while fluidizing the said powder.

The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.

The invention describes novel nitrosated and/or nitrosylated compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for treating ophthalmic disorders. The nitrosated and/or nitrosylated compounds are preferably nitrosated and/or nitrosylated (3-adrenergic antagonists and nitrosated and/or nitrosylated angiotensin-converting enzyme (ACE) inhibitors.

The invention discloses an antihypertensive peptide of a swim bladder of a large yellow croaker and a preparation method and use thereof. The amino acid sequence of the antihypertensive peptide is Leu-Arg-Pro-Ile(SEQ ID No:1). The molecular weight detected through ESI-MS (Electrospray Ionization Mass Spectrometry) is 497.65Da([M+H]+498.48Da). The preparation method comprises the following steps: washing the swim bladder of the large yellow croaker by distilled water, homogenizing by a high speed tissue stamp mill, extracting by a Na2HPO4-NaH2PO4 buffer liquid, and fractionally precipitating by ammonium sulfate to obtain a coarse protein; and sequentially carrying out enzymolysis on the coarse protein by trypsin and alkaline protease, centrifugalizing, ultrafiltering and chromatographically refining the zymolyte to obtain the antihypertensive peptide. The preparation process of the antihypertensive peptide disclosed by the invention is scientific and reasonable, the enzymolysis process by double enzymes is easy to control, and the prepared antihypertensive peptide has a remarkable inhibiting effect on the angiotensin converting enzyme (ACE), has the advantages of easy digestive absorption, safety, no toxic and side effects and the like and can be used as a medicine and a health-care food.

The invention provides an albumin angiotensin converting enzyme inhibition peptide and a preparation method thereof, belonging to the biotechnology field. A new active peptide with angiotensin converting enzyme inhibition function is separated and purified from albumin zymolyte and has a sequence of RVPSL. The preparation method comprises the steps of: carrying out the enzymolysis on albumin to prepare the zymolyte, purifying the albumin angiotensin converting enzyme inhibition peptide, identifying the structure of the albumin angiotensin converting enzyme inhibition peptide, synthesizing the albumin angiotensin converting enzyme inhibition peptide and checking the activity of the albumin angiotensin converting enzyme inhibition peptide. The invention can be used for preparing antihypertensive drugs and functional foods assisting blood pressure reduction.

The invention relates to a lactobacillus and in particular relates to a low-temperature resistant lactobacillus with ACE (angiotensin converting enzyme) inhibitory activity. The low-temperature resistant lactobacillus with the ACE inhibitory activity is lactobacillus plantarum I1 which is preserved in the China general microbiological culture collection center of which the preservation address is No.3, No1. yard, Beichen west road, Chaoyang District of Beijing, the preservation data is September 18th, 2012, and the preservation number is CGMCC No.6575; the lactobacillus plantarum I1 has the ACE inhibitory rate being 66%, can tolerate 6% of NaCl and 100mg/kg of nitrite, and can fast generate acid; the growing temperature of the lactobacillus plantarum I1 is 4-40 DEG C, and is suitable for low-temperature fermentation; and the low-temperature resistant lactobacillus has obvious protease activity and lipase activity, can not generate mucus, has an obvious antibacterial effect on staphylococcus aureus and colon bacillus, and can be used as a meat product leavening agent strain under a low-temperature condition.